[A17-63] Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

Last updated 01.03.2018

Project no.:
A17-63

Commission:
Commission awarded on 01.12.2017 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

Adults with moderate to severe atopic dermatitis who are candidates for systemic treatment

Result of dossier assessment:

Indication of a non-quantifiable added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

01.03.2018

Dupilumab for neurodermatitis: indication of an added benefit in adults

Clear advantages in symptoms and particularly in quality of life / dossier provides informative data

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2018-05-17 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.